Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives
Eugenia Cella,Lodovica Zullo,Silvia Marconi,Giovanni Rossi,Simona Coco,Chiara Dellepiane,Angela Alama,Leslie Rozeboom,Elisa Bennicelli,Francesca Parisi,Gianluca Sacco,Giulia Barletta,Linda Zinoli,Marco Tagliamento,Paolo Pronzato,Carlo Genova
DOI: https://doi.org/10.1080/14712598.2022.2116273
2022-08-30
Expert Opinion on Biological Therapy
Abstract:In recent years, immunotherapy has become a pillar in the treatment of advanced, non-oncogene-addicted non-small cell lung cancer (NSCLC). Programmed death ligand 1 (PD-L1) expression is currently the only factor used to predict response to immunotherapy in clinical practice. Specifically, single-agent pembrolizumab as first-line therapy is approved for tumors with high expression of PD-L1 (≥50%) while immunotherapy and chemotherapy are approved for any PD-L1. However, combinations of immune-checkpoint inhibitors (ICIs) and other agents may confer higher benefit than immunotherapy alone in some circumstances. We reviewed the available data regarding the combined use of ICIs and chemotherapy in patients with advanced, treatment-naïve NSCLC. In light of the benefit demonstrated in advanced disease, these combinations have been subsequently tested in other settings. We collected the most relevant findings regarding efficacy and safety of chemo-immunotherapy combinations in early and locally advanced NSCLC. Immune-chemotherapy combinations demonstrated benefit in the advanced setting, and this strategy in now being applied in the early and local advanced settings. A description of clinical and biological predictors of response is required in order to identify patients who may benefit the most from combination therapy.
medicine, research & experimental,biotechnology & applied microbiology